"Treatment Algorithms: Postherpetic Neuralgia - Lyrica Forms the Cornerstone of Treatment for Postherpetic Neuralgia" - New Market Report
Prescribing trends reveal that patients with PHN are typically initiated on monotherapy. Since no single therapy provides sufficient efficacy, physicians increasingly turn to combination therapy at later lines of treatment to optimize patient outcomes. Lyrica (pregabalin; Pfizer) leads the market, with the recent market entrant Gralise (extended-release gabapentin) struggling to make an impact.
View full press release